Dr. Reddy’s voluntarily recalls Rivastigmine Tartrate Capsules from US market
Dr. Reddy’s has recently voluntary recalled Rivastigmine Tartrate Capsules of 1.5 mg strength from the USA market, following 'Failed Dissolution Specifications'. A total of 60 bottles of 2952 units are recalled on the direction of US Food and Drug Administration (USFDA). The batch was manufactured at Dr. Reddy’s, Bachupally unit. Recall was classified as "Class II" classification. . Class II recall is a situation in which the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Rivastigmine Tartrate Capsules are indicated for the treatment of mild to moderate dementia of the Alzheimer's type or Parkinson's disease.